Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.

Keys
Genmab may be unlocking the door to its post-Darzalex future

Genmab AS and immatics biotechnologies GMBH have inked a deal to develop multiple bispecific immunotherapies in oncology.

Looking to follow on from success with Darzalex (daratumumab), the Danish biotech is to gain exclusive access to multiple novel...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category